
CAS 863971-19-1
:Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
6 Produkte.
(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-Dihydro-1H-Pyrrol-1-Yl)-N-Methylhexanamido)-3-Methylbutanamido)-N,3-Dimethylbutanamido)-3-Methoxy-5-Methylheptanoyl)Pyrrolidin-2-Y
CAS:(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-Dihydro-1H-Pyrrol-1-Yl)-N-Methylhexanamido)-3-Methylbutanamido)-N,3-Dimethylbutanamido)-3-Methoxy-5-Methylheptanoyl)Pyrrolidin-2-YReinheit:98%Molekulargewicht:925.16g/molMcMMAF
CAS:<p>McMMAF is a protective group-conjugated MMAF.</p>Formel:C49H76N6O11Reinheit:99.65% - >99.99%Farbe und Form:SolidMolekulargewicht:925.16MC-MMAF
CAS:<p>MC-MMAF is an antibody that binds to the epidermal growth factor receptor (EGFR) on tumor cells and inhibits the proliferation of tumor cells by blocking the binding of epidermal growth factor. MC-MMAF has been shown to be an effective treatment for a variety of cancers, including breast cancer, lung cancer, head and neck cancer, and colorectal cancer. It is also being studied as a potential treatment for autoimmune diseases such as rheumatoid arthritis and psoriasis. MC-MMAF has been shown to improve prognosis in patients with glomerular filtration rate (GFR) less than 30 mL/min per 1.73 m2.</p>Formel:C49H76N6O11Reinheit:Min. 95 Area-%Farbe und Form:White PowderMolekulargewicht:925.16 g/molMafodotin
CAS:Kontrolliertes Produkt<p>Applications Mafodotin is an anticancer immunoconjugate for the diagnosis and treatment of cancer or B Cell proliferative diseases.<br>References Valliere-Douglass, J.F., et al.: Anal. Chem., 84, 2843 (2012); Alley, S.C., et al.: Bioconjugate. Chem., 19, 759 (2008); Doronina, S.O., et al.: Bioconjugate. Chem., 17, 114 (2006);<br></p>Formel:C49H76N6O11Farbe und Form:NeatMolekulargewicht:925.1613




